A combination of empagliflozin and curcumin significantly reduced fatty liver disease development in mice by improving fat metabolism and reducing liver inflammation, according to research reviewed by Gram Research. In a 23-week study, mice receiving both treatments together gained less weight, had less liver fat, and showed better liver health markers than mice receiving either treatment alone or no treatment, suggesting this combination approach may offer promise for future human therapies.
Researchers tested a combination of two substances, empagliflozin (a diabetes medication) and curcumin (a compound from turmeric), to see if they could prevent fatty liver disease in mice fed a high-fat diet. According to Gram Research analysis, the combination worked better than either treatment alone, reducing liver fat buildup, helping the body burn more calories, and reducing harmful inflammation in the liver. The mice that received both treatments gained less weight and showed improved markers of liver health compared to mice receiving just one treatment or no treatment.
Key Statistics
A 2026 animal study found that co-administration of empagliflozin and curcumin in high-fat diet-fed mice produced synergistic effects, with the combination group showing significantly greater reductions in body weight gain and hepatic steatosis compared to either treatment alone.
Research in mice demonstrated that the empagliflozin and curcumin combination most effectively activated the Nrf2 protective pathway in liver cells and reduced oxidative stress markers, with benefits exceeding those observed in single-treatment groups.
In the 23-week study, mice receiving combined empagliflozin and curcumin treatment showed the most pronounced browning of white adipose tissue on 18F-FDG PET/CT imaging and improved cold tolerance, indicating enhanced systemic energy expenditure.
The Quick Take
- What they studied: Whether combining a diabetes drug (empagliflozin) with turmeric extract (curcumin) could prevent or reduce fatty liver disease in mice eating a high-fat diet
- Who participated: Male laboratory mice (C57BL/6J strain) divided into groups: some ate normal food, others ate high-fat food, and some high-fat diet mice received the treatments for 23 weeks
- Key finding: Mice receiving both empagliflozin and curcumin together had significantly less liver fat, gained less weight, and showed better liver health markers than mice receiving either treatment alone or no treatment
- What it means for you: This research suggests a potential new combination approach for treating fatty liver disease, though human studies are needed before this could become a medical treatment. The findings are promising but preliminary.
The Research Details
Researchers conducted an animal study using laboratory mice to test whether combining two substances could prevent fatty liver disease. Male mice were divided into different groups: some ate a normal diet while others ate a high-fat diet designed to cause fatty liver disease. Among the high-fat diet mice, some received empagliflozin (a medication used to treat type 2 diabetes), some received curcumin (a natural compound found in turmeric), some received both treatments together, and some received no treatment. The study lasted 23 weeks, which is a significant portion of a mouse’s lifespan. Researchers measured multiple markers of liver health, body weight, and how well the mice’s bodies burned calories.
Testing combinations of treatments in animals before human trials helps researchers understand whether two substances work better together than separately. This approach, called synergistic effects, can reveal new treatment possibilities. The researchers used advanced imaging technology (PET/CT scans) to visualize how the treatments affected fat tissue in the mice’s bodies, providing detailed information about the mechanisms at work.
This was a controlled laboratory study with clear comparison groups, which is a solid research design. However, because it was conducted in mice rather than humans, the results may not directly translate to people. The study measured multiple health markers, which strengthens confidence in the findings. The specific statistical significance values were reported (p values), indicating the results were unlikely due to chance.
What the Results Show
The combination of empagliflozin and curcumin produced the strongest benefits across all measured outcomes. Mice receiving both treatments gained significantly less weight compared to mice eating high-fat food without treatment. The combination treatment most effectively reduced fat accumulation in the liver, which is the core problem in fatty liver disease. Liver inflammation and oxidative stress (cellular damage from harmful molecules) were reduced most dramatically in the combination group. The researchers observed that the combination activated a protective pathway in liver cells called the Nrf2 pathway, which helps cells defend themselves against damage.
The combination treatment also increased browning of white fat tissue, meaning the body converted regular fat into a type of fat that burns calories to produce heat. This increased calorie burning throughout the body. Mice receiving the combination showed better cold tolerance, suggesting their bodies were more efficient at generating heat. These secondary findings indicate the treatments work through multiple mechanisms, not just by reducing liver fat.
Empagliflozin is already known to have benefits for metabolic health beyond its use in diabetes treatment. Curcumin has been studied for anti-inflammatory properties for many years. This research builds on previous work by testing whether combining these two substances produces better results than either alone. The synergistic effect observed here (where the combination worked better than expected from adding the individual effects) suggests a new direction for fatty liver disease treatment research.
This study was conducted only in mice, so results may not directly apply to humans. The study did not test different doses or treatment durations, so optimal dosing remains unknown. Only male mice were studied, so the effects in females remain unclear. The research was relatively short-term (23 weeks), so long-term safety and effectiveness are unknown. No human trials have been conducted yet, so this remains preliminary research.
The Bottom Line
This research is too early-stage to recommend these treatments for human use. Empagliflozin is already approved for diabetes treatment, but using it specifically for fatty liver disease would require human clinical trials. Curcumin supplements are available but lack strong evidence for fatty liver disease treatment. Anyone with fatty liver disease should work with their healthcare provider on proven approaches like weight loss, reduced sugar intake, and exercise.
This research is most relevant to scientists and medical researchers studying fatty liver disease treatment options. People with metabolic dysfunction-associated steatotic liver disease (MASLD) or non-alcoholic fatty liver disease may find this research interesting as a potential future treatment direction. Healthcare providers treating liver disease should monitor this research as it develops toward human trials.
This is basic research in animals. If human trials begin, it typically takes 5 to 10 years for a new treatment combination to move from initial testing to potential medical use. Proven treatments for fatty liver disease today focus on lifestyle changes, which can show benefits within weeks to months.
Frequently Asked Questions
Can I take empagliflozin and curcumin together to treat fatty liver disease?
This combination has only been tested in mice, not humans. Empagliflozin is a prescription diabetes medication requiring medical supervision. Curcumin supplements are available but lack strong evidence for liver disease. Consult your doctor about proven treatments like weight loss and exercise before considering experimental combinations.
What is fatty liver disease and why is it a problem?
Fatty liver disease occurs when fat accumulates in liver cells, reducing the liver’s ability to function properly. It can lead to inflammation, scarring, and eventually liver failure if untreated. Lifestyle changes including weight loss, reduced sugar intake, and regular exercise are currently the most effective treatments.
How does curcumin help with liver health?
Curcumin, found in turmeric, has anti-inflammatory and antioxidant properties that may protect liver cells from damage. In this mouse study, curcumin combined with empagliflozin reduced liver inflammation and activated protective cellular pathways, though human evidence remains limited.
When will this treatment be available for people?
This research is in early stages with only animal testing completed. If human trials begin, it typically takes 5 to 10 years for a new treatment to reach patients. Currently, proven approaches for fatty liver disease focus on lifestyle modifications rather than medication combinations.
What should I do if I have fatty liver disease?
Work with your healthcare provider on proven strategies: lose 5 to 10 percent of body weight, reduce high-fat and high-sugar foods, exercise regularly, and limit alcohol. These approaches show measurable improvements within weeks to months and remain the gold standard for treatment.
Want to Apply This Research?
- Track weekly body weight and energy levels to establish a baseline, then monitor changes if lifestyle modifications are implemented. Record any dietary changes and exercise frequency to correlate with health improvements.
- Users can implement evidence-based lifestyle changes for liver health: reduce high-fat food intake, increase physical activity to 150 minutes weekly, and track weight loss progress. The app can remind users to log meals and exercise, creating accountability for the proven interventions.
- Establish monthly weight tracking and quarterly liver health marker monitoring through healthcare providers. Use the app to log dietary choices, exercise, and any symptoms. Compare trends over 3 to 6 months to assess whether lifestyle changes are producing measurable improvements.
This research was conducted in laboratory mice and has not been tested in humans. The findings are preliminary and should not be interpreted as medical advice or recommendations for human treatment. Empagliflozin is a prescription medication that should only be used under medical supervision. Curcumin supplements are not regulated by the FDA and their safety and effectiveness for liver disease are not established. Anyone with fatty liver disease should consult with a qualified healthcare provider before starting any new treatment, supplement, or medication. This article is for educational purposes only and does not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.